Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Carl June
Research
China approved the first solid tumor CAR-T. Will the US follow?
While satri-cel may soon broaden its reach to more Chinese patients, the game-changing therapy is unlikely to hit the American market anytime soon.
Darren Incorvaia
Jun 30, 2026 10:00am
BMS-backed Dispatch unveils with $216M, Carl June as cofounder
Jul 23, 2025 6:30am
Carl June, Vertex execs among 2024's Breakthrough Prize winners
Sep 15, 2023 8:00am
Epitope edited CAR-Ts show ability to target all blood cancers
Sep 1, 2023 9:00am
A CAR-T cell gel kills residual cancer cells after surgery
Jan 20, 2023 9:35am
Carl June's latest CAR-T work taps llamas for GI cancers
Mar 29, 2022 9:00am
